ROYALTY PHARMA PLC
Ownership & governance
Executives 5Directors 9Avg age 61Avg tenure 7.6y
PL
Pablo Legorreta
Chief Executive Officer
Age 62Since 1995-12-31Profile →
+13
Executives5
PL
Pablo Legorreta→
Chief Executive Officer
Age 62Since 1995-12-31
TC
Terrance Coyne
Director of Finance/CFO
Age 44Since 2009-12-31
ES
Eric Schneider
Chief Tech/Sci/R&D Officer
—Since 2023-09-20
AM
Arthur McGivern→
Chief Investment Officer
—Since 2022-10-11
SK
Sara Klymkowsky
Chief Tech/Sci/R&D Officer
—Since 2011-12-31
Board of directors9
PL
Pablo Legorreta→
Chairman
Age 62Since 2020-03-31
GN
Gregory Norden→
Director/Board Member
Age 68Since 2020-02-10
BB
Bonnie Bassler→
Director/Board Member
Age 63Since 2020-06-15
TL
Ted Love→
Director/Board Member
Age 67Since 2020-07-29
CE
Catherine Engelbert→
Director/Board Member
Age 61Since 2020-06-15
DH
David Hodgson→
Director/Board Member
Age 69Since 2022-06-22
VC
Vladimir Coric→
Director/Board Member
Age 55Since 2025-04-07
CH
Carole Ho→
Director/Board Member
Age 53Since 2025-07-16
Shareholders5
| Name | Stake | Shares |
|---|---|---|
| Eaton Vance Management | 9.83 % | 43,571,633 |
| Capital Research & Management Co. (International Investors) | 7.897 % | 35,005,736 |
| Fidelity Management & Research Co. LLC | 5.673 % | 25,145,415 |
| R & H Trust Co. Ltd. | 4.82 % | 21,366,927 |
| BlackRock Advisors LLC | 4.634 % | 20,540,416 |
Catalog · 2026-07-09
Proxy officers27
| Name | Role | Since | Shares |
|---|---|---|---|
| Pablo Legorreta | Chairman | 2020-03-31 | - |
| Arthur McGivern | Director or executive officer | — | 706,393 |
| Arthur McGivern | Director or executive officer | — | 706,393 |
| Bonnie Bassler | Director/Board Member | 2020-06-15 | - |
| Bonnie Bassler, Ph.D | Director or executive officer | 2020-06-01 | 73,947 |
| Carole Ho | Director/Board Member | 2025-07-16 | - |
| Carole Ho, M.D | Director or executive officer | 2025-07-01 | 8,558 |
| Catherine Engelbert | Director or executive officer | 2020-06-01 | 51,128 |
Proxy · as of 2026-07-09
Group companies
| Name | Category |
|---|---|
| Royalty Pharma Holdings Ltd. | Financial Conglomerates |
| Royalty Pharma Holdings Ltd. | Financial Conglomerates |
Institutional (13F)
Loading Form 13F holders…
Fund membership
Loading fund baskets…
Street consensus
Consensus strong buyMean target 65.38Range 61–70Analysts 8
61Mean 65.3870
- Strong buy 2
- Buy 5
- Hold 1
Broker actions40 of 49
| Firm | Action | To | Target | Date |
|---|---|---|---|---|
| Morgan Stanley | Maintained | Overweight | 67 | 2026-10-07 |
| TD Cowen | Maintained | Buy | 68 | 2026-09-08 |
| JP Morgan | Maintained | Overweight | 62 | 2026-08-07 |
| TD Cowen | Maintained | Buy | 65 | 2026-07-13 |
| Citigroup | Maintained | Buy | 66 | 2026-05-07 |
| JP Morgan | Maintained | Overweight | 58 | 2026-05-07 |
| UBS | Maintained | Buy | 57 | 2026-04-21 |
| Morgan Stanley | Maintained | Overweight | 63 | 2026-04-10 |
| UBS | Upgrade | Buy | 49 | 2026-01-30 |
| Citigroup | Maintained | Buy | 50 | 2026-01-27 |
| TD Cowen | Maintained | Buy | 45 | 2025-12-11 |
| Morgan Stanley | Maintained | Overweight | 54 | 2025-10-10 |
Firm rows and rating mix from Yahoo Finance; mean target is Yahoo’s aggregate until OpenFilings derives consensus from broker rows.